Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal for immunotherapy of cancer·2026

Same author

Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

European journal of cancer (Oxford, England : 1990)·2026

Same author

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Clinical pharmacokinetics·2026

Same journal

En face localization of retinal telangiectatic capillaries using OCT compared with ICG angiography in chronic vascular macular oedema.

Acta ophthalmologica·2026

Same journal

Usher syndrome-related visual impairment in Finland: A 35-year nationwide register-based study (1985-2019).

Acta ophthalmologica·2026

Same journal

Three years of ocular proton therapy in the Netherlands, clinical results.

Acta ophthalmologica·2026

Same journal

Risk factors for acquisition and severity of Acanthamoeba and Fusarium keratitis in contact lens users-A case-control and clinical-epidemiological study, 2009-2020.

Acta ophthalmologica·2026

Same journal

Distinguish polypoidal choroidal vasculopathy through choroidal alterations: A systematic review, meta-analysis and narrative synthesis.

Acta ophthalmologica·2026

Same journal

Ocular blood flow and retinal oxygen saturation measurements in central retinal artery occlusion.

Acta ophthalmologica·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 14, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Tumour progression shows decrease in PD-L1 expression in matched metastases/primary uveal melanomas.

Maria Chiara Gelmi¹, Gulçin Gezgin¹, Ellen Kapiteijn²

¹Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.

Acta Ophthalmologica

|July 24, 2025

Summary

This summary is machine-generated.

Metastatic uveal melanoma (UM) shows lower PD-L1 expression and higher T-cell infiltration than primary UM, potentially explaining poor response to immune checkpoint inhibitors (ICI). Primary tumors may benefit more from ICI therapy.

Keywords:

immune checkpoint metastases microenvironment uveal melanoma

More Related Videos

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Related Experiment Videos

Last Updated: Sep 14, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Area of Science:

Oncology
Immunology
Pathology

Background:

Immune checkpoint inhibitors (ICI) have transformed cancer treatment but show limited efficacy in metastatic uveal melanoma (UM).
Understanding the tumor microenvironment in UM is crucial for improving ICI therapy outcomes.

Purpose of the Study:

To investigate the expression of PD-1, PD-L1, T-cell, and macrophage markers in primary and metastatic UM.
To elucidate the reasons behind the unsatisfactory response to ICI in metastatic UM.

Main Methods:

Immunohistochemical (IHC) staining of 32 UM samples (13 primary, 19 metastases) for PD-L1, PD1, CD3, CD4, CD8, CD68, CD163, HLA class I, and BAP1.
Quantitative and semiquantitative scoring of markers and comparison between primary and metastatic UM, including matched cases.

Main Results:

Metastatic UM exhibited significantly lower PD-L1 expression on tumor cells compared to primary UM.
UM metastases showed increased T-cell infiltration (including PD1 expression) but no difference in macrophage infiltration.
Low HLA Class I expression in metastases correlated with absent PD-L1 and PD1 expression; BAP-1 loss was linked to higher lymphocytic infiltration.

Conclusions:

Lower PD-L1 expression in UM metastases, despite increased lymphocytic infiltrate, may explain the limited effectiveness of ICI.
Primary UM might be more responsive to ICI therapy than metastases.
Targeting primary tumors in a neoadjuvant or adjuvant setting could be beneficial for high-risk patients.